Low-dose statin therapy improves endothelial function in type 2 diabetic patients with normal serum total cholesterol: a randomized placebo-controlled study

J Clin Hypertens (Greenwich). 2010 Oct;12(10):820-5. doi: 10.1111/j.1751-7176.2010.00367.x. Epub 2010 Aug 20.

Abstract

The authors sought to explore the effect of low-dose atorvastatin on endothelial function in normocholesterolemic patients with type 2 diabetes mellitus without evidence of coronary disease. Sixty patients with type 2 diabetes mellitus, normal serum cholesterol, and normal exercise test results were enrolled. Initial assessment was performed by measurement of the brachial artery diameter and flow velocity both at baseline and after induced hyperemia. Patients were randomly assigned to receive either atorvastatin 10 mg daily for 4 weeks (atorvastatin group=30 patients) or matched placebo for the same period (placebo group=30 patients). Follow-up assessment of the brachial artery diameter and flow velocity (both baseline and hyperemic) was performed after 4 weeks. Initially, no significant difference was found between the two groups regarding brachial artery diameter or flow velocity, both at baseline and at peak hyperemia (P>.05 for all). At follow-up, there was a significantly higher flow velocity at baseline (P<.05) and a significantly higher percent increase of brachial artery diameter (from baseline to peak hyperemia) in the atorvastatin group (P<.05). In patients with type 2 diabetes mellitus and normal serum cholesterol without evidence of coronary disease, low-dose atorvastatin improves endothelial function.

Publication types

  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Anticholesteremic Agents / therapeutic use*
  • Atorvastatin
  • Brachial Artery
  • Cholesterol / metabolism*
  • Diabetes Mellitus, Type 2 / pathology*
  • Endothelium, Vascular / drug effects*
  • Exercise Test
  • Female
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Male
  • Placebos
  • Pyrroles / therapeutic use*
  • Statistics, Nonparametric
  • Time Factors

Substances

  • Anticholesteremic Agents
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Placebos
  • Pyrroles
  • Cholesterol
  • Atorvastatin